Tradestie Institutional Equity Comparison Engine

RCEL vs MXCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RCEL Overall Edge

RCEL Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avita Medical, Inc. Common Stock (RCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RCEL trades at 10.3x Forward P/E with -33.9% operating margin (+53.1% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, RCEL sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner RCEL
RCEL 10.3x vs MXCT N/M Fwd P/E
Growth & Margin Winner RCEL
Op Margin -33.9% vs -85.5% ยท YoY +53.1% vs +48.7%
Momentum & Technical Winner RCEL
1Y +295.4% vs -19.4% ยท 52W Pos 82% vs 63%
Options & Structure Winner RCEL
CONSOLIDATION (6th %ile IV) vs UNCLASSIFIED (N/A IV)
RCEL NASDAQ
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
1M Return +1.3%
1Y Return +295.44%
Forward P/E 10.3x
Unified AI Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
1M Return -4.2%
1Y Return -19.41%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RCEL +295.44% MXCT -19.41% Spread: +314.85 pp (RCEL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RCEL Revenue MXCT Revenue RCEL Op. Margin MXCT Op. Margin Margin Edge
FY2018 $0M N/A -1489.9% N/A RCEL
FY2019 $10M $10M -466.4% -93.7% MXCT
FY2020 $10M $20M -299.2% -71.6% MXCT
FY2021 $30M $20M -90.8% -84.3% MXCT
FY2022 $30M $30M -79.9% -95.2% RCEL
FY2023 $50M $20M -85.1% -247.7% RCEL
FY2024 $60M $20M -88.1% -230.5% RCEL
FY2025 $70M $20M -59.4% -247.6% RCEL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RCEL (9) vs MXCT (1)
Institutional Metric RCEL MXCT Criterion Row Winner
Market Capitalization Scale $506.7M $132.2M Larger Scale RCEL
Trailing P/E Ratio Valuation 10.3x N/M Lower Multiple RCEL
Forward P/E Ratio Valuation 10.3x N/M Lower Multiple RCEL
Revenue Growth (YoY) Growth +53.1% +48.7% Higher Growth RCEL
Operating Margin (TTM) Profitability -33.9% -85.5% Higher Margin RCEL
Net Profit Margin Profitability -42.6% -81.4% Higher Margin RCEL
Return on Equity (ROE) Capital Efficiency -1746.3% -16.9% Higher ROE MXCT
52-Week Range Position Momentum 82% ($3โ€“$18) 63% ($1โ€“$2) Stronger Trend RCEL
Beta / 30D Volatility Risk Regime 1.54ฮฒ ยท 65% Vol 1.19ฮฒ ยท 96% Vol Lower Realized Risk RCEL
Unified Institutional Score Composite Signal 45.6 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite RCEL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RCEL vs MXCT Buy Guide
RCEL CONSOLIDATION
17d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live RCEL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MXCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RCEL nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.